Benign prostatic hyperplasia/urinary retention:
Indications for: CARDURA XL
Swallow whole. Take w. breakfast. Initially 4mg once daily; may titrate after 3–4 weeks to max 8mg/day. If therapy is stopped for several days, restart at 4mg once daily. Switching from Cardura to Cardura XL: initially 4mg once daily; do not take final evening dose of Cardura. Concomitant PDE-5 inhibitors: initiate at lowest dose.
CARDURA XL Warnings/Precautions:
Severe hepatic impairment: not recommended. Mild or moderate hepatic impairment. Syncope. Symptomatic hypotension. Exclude prostate cancer. Severe GI narrowing. Coronary insufficiency; discontinue if angina pectoris appears or worsen. Cataract surgery (intraoperative floppy iris syndrome possible). Elderly. Pregnancy, nursing mothers: not indicated for females.
CARDURA XL Classification:
CARDURA XL Interactions:
Caution with strong CYP3A4 inhibitors (eg, atanazavir, clarithromycin, indinavir, ketoconazole, itraconazole, nefazodone, others). Additive hypotension with concomitant PDE-5 inhibitors.
Headache, dizziness, asthenia, hypotension, dyspnea, postural hypotension, somnolence, respiratory or urinary tract infections; rare: priapism.